On the function of β3-adrenoceptors in the human heart: Signal transduction, inotropic effect and therapeutic prospects;Zur funktion des β3-adrenozeptors am herzen: Signaltransduktion, inotroper effekt und therapeutischer ausblick

Wiener Medizinische Wochenschrift

Volumn 156, Issue 15-16, 2006, Pages 451-458

  Pott, Christian ^a,f   Steinritz, Dirk ^c,d   Napp, Andreas ^b   Bloch, Wilhelm ^c   Schwinger, Robert H G ^b,e   Brixius, Klara ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c Institut für Kreislaufforschung und Sportmedizin Abteilung für Molekulare und Zellula re Sportmedizin Deutsche Sporthochschule Köln   (Germany)

^d BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

^e Klinikum Weiden   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 adrenoceptor; Adrenergic stimulation; Failing heart; Myocardium; Nitric oxide

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CATECHOLAMINE; ETHANOLAMINE DERIVATIVE; NITRIC OXIDE SYNTHASE;

BETA ADRENERGIC STIMULATION; DRUG MECHANISM; ENZYME ACTIVATION; HEART; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HUMAN; INOTROPISM; MENTAL STRESS; PHYSICAL STRESS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG POTENTIATION; HEART CONTRACTION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADRENERGIC BETA-AGONISTS; CATECHOLAMINES; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ETHANOLAMINES; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL CONTRACTION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 33749002843     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-006-0273-x     Document Type: Review

References (66)

1. 1-receptor down-regulation in heart failure. Circ Res 59(3): 297-309
2. Wallukat G (2002) The β-adrenergic receptors. Herz 27(7): 683-690
3. 2-adrenergic stimulation or cyclic AMP elevation in vivo. Br J Pharmacol 129(5): 969-974
4. 2+ current in cat atrial myocytes. J Physiol 542(Pt 3): 711-723
5. 3- adrenoceptor knockout mice. Mol Pharmacol 53(4): 670-675
6. 4-adrenoceptor pharmacology. Naunyn Schmiedebergs Arch Pharmacol 363(1): 87-93
7. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46(2): 121-136
8. Leineweber K, Buscher R, Bruck H, Brodde OE (2004) β-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369(1): 1-22
9. 3-adrenergic receptor. Science 245(4922): 1118-1121
10. 3-adrenergic receptor gene. Mol Pharmacol 44(2): 264-270
11. 3- adrenoceptors in human colon. Br J Pharmacol 120(8): 1527-1535
12. 3-adrenoceptor agonists of differing selectivities. J Pharmacol Exp Ther 285(3): 1084-1095
13. 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol 128(1): 69-76
14. 3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103(12): 1649-1655
15. 3- adrenoceptor in human adipose tissue, atrium and skeletal muscle. Int J Obes Relat Metab Disord 23(10): 1057-1065
16. 3-adrenergic activation of adenylyl cyclase in mouse white adipocytes: modulation by GTP and effect of obesity. J Cell Biochem 58(4): 464-473
17. 3-adrenergic receptors with Gi in rat adipocytes. Cell Signal 6(4): 457-465
18. 3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 102(7): 1377-1384
19. Balligand JL, Kobzik L, Han X, Kaye DM, Belhassen L, O'Hara DS, Kelly RA, Smith TW, Michel T (1995) Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 270(24): 14582-14586
20. 3-adrenoceptors in human atrial myocardium. Br J Pharmacol 138(3): 521-529
21. 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium. Br J Pharmacol 143(8): 1014-1022
22. Goligorsky MS, Li H, Brodsky S, Chen J (2002) Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am J Physiol Renal Physiol 283(1): F1-10
23. Bloch W, Mehlhorn U, Krahwinkel A, Reiner M, Dittrich M, Schmidt A, Addicks K (2001) Ischemia increases detectable endothelial nitric oxide synthase in rat and human myocardium. Nitric Oxide 5(4): 317-333
24. Michel JB, Feron O, Sase K, Prabhakar P, Michel T (1997) Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol Chem 272(41): 25907-25912
25. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399(6736): 601-605
26. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399(6736): 597-601
27. 2+/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 88(11): E68-75
28. 2+ in human atrial myocardium. Am J Physiol Cell Physiol [Epub ahead]
29. El-Armouche A, Zolk O, Rau T, Eschenhagen T (2003) Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure. Cardiovasc Res 60(3): 478-487
30. Brady AJ, Warren JB, Poole-Wilson PA, Williams TJ, Harding SE (1993) Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 265(1 Pt 2): H176-82
31. 3- and atypical β-adrenoceptors. Med Res Rev 13(6): 663-729
32. 3-adrenoceptor agonist BRL35135 in man. Br J Clin Pharmacol 37(4): 363-369
33. 3-adrenoceptor in the human heart. J Clin Invest 98(2): 556-562
34. 3-adrenoceptor stimulation in the beating guinea pig heart. J Cardiovasc Pharmacol 35(5): 786-790
35. 3-adrenergic receptor. Cardiovasc Res 59(2): 288-296
36. Keaney JF Jr, Hare JM, Balligand JL, Loscalzo J, Smith TW, Colucci WS (1996) Inhibition of nitric oxide synthase augments myocardial contractile responses to β-adrenergic stimulation. Am J Physiol 271(6 Pt 2): H2646-652
37. Chesnais JM, Fischmeister R, Mery PF (1999) Positive and negative inotropic effects of NO donors in atrial and ventricular fibres of the frog heart. J Physiol 518 (Pt 2): 449-461
38. Massion PB, Feron O, Dessy C, Balligand JL (2003) Nitric oxide and cardiac function: ten years after, and continuing. Circ Res 93(5): 388-398
39. 3- adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21(11): 426-431
40. 3-adrenoceptor: physiological role and potential therapeutic applications. Acta Clin Belg 55(4): 209-214
41. Chidsey CA, Braunwald E, Morrow AG (1965) Catecholamine Excretion and Cardiac Stores of Norepinephrine in Congestive Heart Failure. Am J Med 39: 442-451
42. Gaffney TE, Braunwald E (1963) Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 34: 320-324
43. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 307(4): 205-211
44. Schwinger RH, Bohm M, Erdmann E (1990) Evidence against spare or uncoupled β-adrenoceptors in the human heart. Am Heart J 119(4): 899-904
45. Bristow MR (2000) beta-adrenergic receptor blockade in chronic heart failure. Circulation 101(5): 558-569
46. 2-adrenergic receptor. Proc Natl Acad Sci USA 90: 3665-3669
47. Strosberg AD (1993) Structure, function, and regulation of adrenergic receptors. Protein Sci 2(8): 1198-1209
48. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T (1993) Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci U S A 90(1): 347-351
49. Feron O, Dessy C, Opel DJ, Arstall MA, Kelly RA, Michel T (1998) Modulation of the endothelial nitric-oxide synthase-caveolin interaction in cardiac myocytes. Implications for the autonomic regulation of heart rate. J Biol Chem 273(46): 30249-30254
50. Heymes C, Vanderheyden M, Bronzwaer JG, Shah AM, Paulus WJ (1999) Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 99(23): 3009-3016
51. Chambers JW, Voss GS, Snider JR, Meyer SM, Cartland JL, Wilson RF (1996) Direct in vivo effects of nitric oxide on the coronary circulation. Am J Physiol 271(4 Pt 2): H1584-1593
52. Loke KE, Laycock SK, Mital S, Wolin MS, Bernstein R, Oz M, Addonizio L, Kaley G, Hintze TH (1999) Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation 100(12): 1291-1297
53. Lefer AM, Lefer DJ (1996) The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovasc Res 32(4): 743-751
54. Liu P, Xu B, Forman LJ, Carsia R, Hock CE (2002) L-NAME enhances microcirculatory congestion and cardiomyocyte apoptosis during myocardial ischemia-reperfusion in rats. Shock 17(3): 185-192
55. Massion PB, Moniotte S, Balligand JL (2001) Nitric oxide: does it play a role in the heart of the critically ill? Curr Opin Crit Care 7(5): 323-336
56. 3- adrenoceptor antagonists in heart failure therapy. Cardiovasc Drug Rev 20(1): 19-26
57. 3-agonists, CGP 12177A and BRL 37344, on coronary flow and contractility in isolated guinea pig heart. J Cardiovasc Pharmacol 41(5): 706-713
58. 3-adrenoceptor. J Pharm Pharmacol 55(1): 95-101
59. Saccomanni G, Badawneh M, Adinolfi B, Calderone V, Cavallini T, Ferrarini PL, Greco R, Manera C, Testai L (2003) Synthesis and beta-blocking activity of (R,S)-(E)-oximeethers of 2,3-dihydro-1,8-naphthyridine and 2,3- dihydrothiopyrano[2,3-b]pyridine: identification of β3-antagonists. Bioorg Med Chem 11(23): 4921-4931
60. 3- adrenergic receptor antagonists. J Pharmacol Exp Ther 290(2): 649-655
61. 3 adrenoceptors. Br J Pharmacol 144(3): 317-322
62. 3-adrenergic activity. Nippon Yakurigaku Zasshi 120(1): 112P-113P
63. Bundkirchen A, Brixius K, Schwinger RH (2004) β-adrenoceptor antagonists in the treatment of chronic heart failure. Pharmazie 59(2): 83-92
64. Bristow MR (1993) Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol 71(9): 12C-22C
65. 3 adrenoceptor in brown adipose tissue in rats. J Anesth 16(3): 265-267
66. 3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J Cardiovasc Pharmacol 42(2): 232-236